Alnylam Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.05.25	Alnylam : Phase 3 HELIOS-B Study Shows Vutrisiran Reduces Cardiovascular Events In ATTR-CM (RTTNews)
06.08.09	Alnylam Pharmaceuticals Reports Second Quarter 2009 Financial Results (Businesswire)
19.12.08	Alnylam Publishes Pre-Clinical Research on Direct CNS Delivery of RNAi Therapeutics (Businesswire)
05.11.08	Alnylam Pharmaceuticals Reports Third Quarter 2008 Financial Results (Businesswire)
03.11.08	Alnylam and Collaborators Publish Research on a New Class of Chemically Modified RNAi Therapeutics that Target Two Distinct Cellular Mechanisms (Businesswire)
01.10.08	Alnylam Appoints Industry Leader John Schmidt as Chief Scientific Officer (Businesswire)
11.09.08	Instituto de Medicina Molecular, Cenix BioScience, and Alnylam Pharmaceuticals Discover New Pathway for Malaria Infection (Businesswire)
06.08.08	Alnylam Awarded Continued Funding Under U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats (Businesswire)
19.06.08	Alnylam and Kyowa Hakko Form Alliance for the Development and Commercialization of ALN-RSV01 in Asia (Businesswire)
27.05.08	Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics (Businesswire)
28.04.08	Alnylam and Collaborators at MIT Publish Research on the Discovery of 'Lipidoids', a Novel Class of Lipid-Based Molecules for the Delivery of RNAi Therapeutics (Businesswire)
30.03.08	Alnylam Forms New Agreement with Tekmira Related to the Planned Tekmira-Protiva Business Combination (Businesswire)
20.03.08	Alnylam Grants Shanghai GenePharma License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market (Businesswire)
03.03.08	Alnylam Announces Grant of Tuschl II Patent in Japan (Businesswire)
28.01.08	Alnylam Announces Grant of New Patent Covering RNAi Therapeutics in the United Kingdom (Businesswire)
04.01.08	Alnylam and Collaborators Receive LEAPS Award from Michael J. Fox Foundation for Parkinson's Research; Enter into Research Collaboration (Businesswire)
26.11.07	Alnylam Announces Grant of Broad Patent Covering RNAi Therapeutics in Germany (Businesswire)
09.08.07	Alnylam Pharmaceuticals Reports Second Quarter 2007 Financial Results (Businesswire)
09.08.07	Alnylam Awarded $38.6 Million U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats (Businesswire)
09.07.07	Roche and Alnylam Form Major Alliance on RNAi Therapeutics (Businesswire)
26.06.07	Alnylam Initiates Phase II Clinical Trial to Evaluate Safety and Anti-viral Efficacy of ALN-RSV01 in the Treatment of Respiratory Syncytial Virus (RSV) Infection (Businesswire)
28.09.06	Alnylam Awarded $23 Million U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats (Businesswire)
30.04.06	Alnylam Reports Phase I Clinical Safety Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of RSV Infection; Results Reported at the 2006 Pediatric Academic Societies' Annual Meeting (Businesswire)
16.03.06	Alnylam Research on microRNAs Featured in The New England Journal of Medicine; Clinical Applications for 'Antagomirs' Discussed in Review Article (Businesswire)
13.09.05	Alnylam and Isis License Intellectual Property for MicroRNA Gene Involved in Hepatitis C Virus Infection; Role of MicroRNA-122 in Hepatitis C Infection Published in Science (Businesswire)
25.07.05	Alnylam Grants MWG Biotech License to Fundamental RNAi Patents for Applications in the Research Products Market (Businesswire)
12.07.05	Alnylam gewährt Eurogentec Lizenz zu grundlegenden RNAi Patenten für den Forschungsproduktmarkt (Businesswire)
11.05.05	Alnylam Pharmaceuticals Reports First Quarter 2005 Financial Results; (Businesswire)
13.04.05	Alnylam and Benitec Form Alliance on Fundamental Intellectual Property (Businesswire)
25.02.05	Alnylam Data Presented on RNAi Therapeutics for Age-Related Macular De (Businesswire)
22.02.05	Alnylam Pharmaceuticals and the Ludwig Maximilian University Munich Pu (Businesswire)
15.02.05	Alnylam Pharmaceuticals Reports 2004 Financial Results; Solid Financia (Businesswire)
09.02.05	Medtronic and Alnylam Pharmaceuticals to Collaborate on Potential Trea (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Roche Hldg G	265.50	2.04 %	K V
Lonza Grp	569.20	1.43 %	K V
Novartis	94.03	1.40 %	K V
Geberit	613.00	0.79 %	K V
Part Grp Hldg	1’102.00	0.78 %	K V
CieFinRichemont	154.85	-0.67 %	K V
Kuehne+Nagel Int	185.05	-0.80 %	K V
ABB	46.54	-1.61 %	K V
Logitech Intl	68.44	-2.34 %	K V
Holcim	91.02	-2.57 %	K V

Alnylam Pharmaceuticals Aktie VALOR 1806798 / ISIN US02043Q1076

Nachrichten zu Alnylam Pharmaceuticals Inc.

Aktien Top/Flop

Meistgelesene Nachrichten